Global Parkinsons disease Drug Market Research Report 2019

1 Study Coverage

• 1.1 Parkinsons disease Drug Product Introduction
• 1.2 Market Segments
• 1.3 Key Parkinsons disease Drug Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Parkinsons disease Drug Market Size Growth Rate by Type
  • 1.4.2 Carbidopa/Levodopa
  • 1.4.3 Dopamine Receptor Agonists
  • 1.4.4 MAO-Inhibitors
• 1.5 Market by Application
  • 1.5.1 Global Parkinsons disease Drug Market Size Growth Rate by Application
  • 1.5.2 Hospital
  • 1.5.3 Online
  • 1.5.4 Retail Pharmacies
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Parkinsons disease Drug Market Size, Estimates and Forecasts
  • 2.1.1 Global Parkinsons disease Drug Revenue 2015-2026
  • 2.1.2 Global Parkinsons disease Drug Sales 2015-2026
• 2.2 Global Parkinsons disease Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
  • 2.2.1 Global Parkinsons disease Drug Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.2.2 Global Parkinsons disease Drug Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Parkinsons disease Drug Competitor Landscape by Players

• 3.1 Parkinsons disease Drug Sales by Manufacturers
  • 3.1.1 Parkinsons disease Drug Sales by Manufacturers (2015-2020)
  • 3.1.2 Parkinsons disease Drug Sales Market Share by Manufacturers (2015-2020)
• 3.2 Parkinsons disease Drug Revenue by Manufacturers
  • 3.2.1 Parkinsons disease Drug Revenue by Manufacturers (2015-2020)
  • 3.2.2 Parkinsons disease Drug Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Parkinsons disease Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Parkinsons disease Drug Revenue in 2019
  • 3.2.5 Global Parkinsons disease Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Parkinsons disease Drug Price by Manufacturers
• 3.4 Parkinsons disease Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Parkinsons disease Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Parkinsons disease Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Parkinsons disease Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Parkinsons disease Drug Market Size by Type (2015-2020)
  • 4.1.1 Global Parkinsons disease Drug Sales by Type (2015-2020)
  • 4.1.2 Global Parkinsons disease Drug Revenue by Type (2015-2020)
  • 4.1.3 Parkinsons disease Drug Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Parkinsons disease Drug Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Parkinsons disease Drug Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Parkinsons disease Drug Revenue Forecast by Type (2021-2026)
  • 4.2.3 Parkinsons disease Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Parkinsons disease Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)

• 5.1 Global Parkinsons disease Drug Market Size by Application (2015-2020)
  • 5.1.1 Global Parkinsons disease Drug Sales by Application (2015-2020)
  • 5.1.2 Global Parkinsons disease Drug Revenue by Application (2015-2020)
  • 5.1.3 Parkinsons disease Drug Price by Application (2015-2020)
• 5.2 Parkinsons disease Drug Market Size Forecast by Application (2021-2026)
  • 5.2.1 Global Parkinsons disease Drug Sales Forecast by Application (2021-2026)
  • 5.2.2 Global Parkinsons disease Drug Revenue Forecast by Application (2021-2026)
  • 5.2.3 Global Parkinsons disease Drug Price Forecast by Application (2021-2026)

6 North America

• 6.1 North America Parkinsons disease Drug by Country
  • 6.1.1 North America Parkinsons disease Drug Sales by Country
  • 6.1.2 North America Parkinsons disease Drug Revenue by Country
  • 6.1.3 U.S.
  • 6.1.4 Canada
• 6.2 North America Parkinsons disease Drug Market Facts & Figures by Type
• 6.3 North America Parkinsons disease Drug Market Facts & Figures by Application

7 Europe

• 7.1 Europe Parkinsons disease Drug by Country
  • 7.1.1 Europe Parkinsons disease Drug Sales by Country
  • 7.1.2 Europe Parkinsons disease Drug Revenue by Country
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 U.K.
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Parkinsons disease Drug Market Facts & Figures by Type
• 7.3 Europe Parkinsons disease Drug Market Facts & Figures by Application

8 Asia Pacific

• 8.1 Asia Pacific Parkinsons disease Drug by Region
  • 8.1.1 Asia Pacific Parkinsons disease Drug Sales by Region
  • 8.1.2 Asia Pacific Parkinsons disease Drug Revenue by Region
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 South Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Taiwan
  • 8.1.9 Indonesia
  • 8.1.10 Thailand
  • 8.1.11 Malaysia
  • 8.1.12 Philippines
  • 8.1.13 Vietnam
• 8.2 Asia Pacific Parkinsons disease Drug Market Facts & Figures by Type
• 8.3 Asia Pacific Parkinsons disease Drug Market Facts & Figures by Application

9 Latin America

• 9.1 Latin America Parkinsons disease Drug by Country
  • 9.1.1 Latin America Parkinsons disease Drug Sales by Country
  • 9.1.2 Latin America Parkinsons disease Drug Revenue by Country
  • 9.1.3 Mexico
  • 9.1.4 Brazil
  • 9.1.5 Argentina
• 9.2 Central & South America Parkinsons disease Drug Market Facts & Figures by Type
• 9.3 Central & South America Parkinsons disease Drug Market Facts & Figures by Application

10 Middle East and Africa

• 10.1 Middle East and Africa Parkinsons disease Drug by Country
  • 10.1.1 Middle East and Africa Parkinsons disease Drug Sales by Country
  • 10.1.2 Middle East and Africa Parkinsons disease Drug Revenue by Country
  • 10.1.3 Turkey
  • 10.1.4 Saudi Arabia
  • 10.1.5 U.A.E
• 10.2 Middle East and Africa Parkinsons disease Drug Market Facts & Figures by Type
• 10.3 Middle East and Africa Parkinsons disease Drug Market Facts & Figures by Application

11 Company Profiles

• 11.1 Teva
  • 11.1.1 Teva Corporation Information
  • 11.1.2 Teva Description and Business Overview
  • 11.1.3 Teva Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Teva Parkinsons disease Drug Products Offered
  • 11.1.5 Teva Related Developments
• 11.2 Novartis AG
  • 11.2.1 Novartis AG Corporation Information
  • 11.2.2 Novartis AG Description and Business Overview
  • 11.2.3 Novartis AG Sales, Revenue and Gross Margin (2015-2020)
  • 11.2.4 Novartis AG Parkinsons disease Drug Products Offered
  • 11.2.5 Novartis AG Related Developments
• 11.3 GSK
  • 11.3.1 GSK Corporation Information
  • 11.3.2 GSK Description and Business Overview
  • 11.3.3 GSK Sales, Revenue and Gross Margin (2015-2020)
  • 11.3.4 GSK Parkinsons disease Drug Products Offered
  • 11.3.5 GSK Related Developments
• 11.4 AbbVie
  • 11.4.1 AbbVie Corporation Information
  • 11.4.2 AbbVie Description and Business Overview
  • 11.4.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
  • 11.4.4 AbbVie Parkinsons disease Drug Products Offered
  • 11.4.5 AbbVie Related Developments
• 11.5 Merck
  • 11.5.1 Merck Corporation Information
  • 11.5.2 Merck Description and Business Overview
  • 11.5.3 Merck Sales, Revenue and Gross Margin (2015-2020)
  • 11.5.4 Merck Parkinsons disease Drug Products Offered
  • 11.5.5 Merck Related Developments
• 11.6 Boehringer Ingelheim
  • 11.6.1 Boehringer Ingelheim Corporation Information
  • 11.6.2 Boehringer Ingelheim Description and Business Overview
  • 11.6.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
  • 11.6.4 Boehringer Ingelheim Parkinsons disease Drug Products Offered
  • 11.6.5 Boehringer Ingelheim Related Developments
• 11.7 Impax Laboratories
  • 11.7.1 Impax Laboratories Corporation Information
  • 11.7.2 Impax Laboratories Description and Business Overview
  • 11.7.3 Impax Laboratories Sales, Revenue and Gross Margin (2015-2020)
  • 11.7.4 Impax Laboratories Parkinsons disease Drug Products Offered
  • 11.7.5 Impax Laboratories Related Developments
• 11.8 Lundbeck
  • 11.8.1 Lundbeck Corporation Information
  • 11.8.2 Lundbeck Description and Business Overview
  • 11.8.3 Lundbeck Sales, Revenue and Gross Margin (2015-2020)
  • 11.8.4 Lundbeck Parkinsons disease Drug Products Offered
  • 11.8.5 Lundbeck Related Developments
• 11.9 Sun Pharma
  • 11.9.1 Sun Pharma Corporation Information
  • 11.9.2 Sun Pharma Description and Business Overview
  • 11.9.3 Sun Pharma Sales, Revenue and Gross Margin (2015-2020)
  • 11.9.4 Sun Pharma Parkinsons disease Drug Products Offered
  • 11.9.5 Sun Pharma Related Developments
• 11.10 Wockhardt
  • 11.10.1 Wockhardt Corporation Information
  • 11.10.2 Wockhardt Description and Business Overview
  • 11.10.3 Wockhardt Sales, Revenue and Gross Margin (2015-2020)
  • 11.10.4 Wockhardt Parkinsons disease Drug Products Offered
  • 11.10.5 Wockhardt Related Developments
• 11.1 Teva
  • 11.1.1 Teva Corporation Information
  • 11.1.2 Teva Description and Business Overview
  • 11.1.3 Teva Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Teva Parkinsons disease Drug Products Offered
  • 11.1.5 Teva Related Developments
• 11.12 Bausch Health
  • 11.12.1 Bausch Health Corporation Information
  • 11.12.2 Bausch Health Description and Business Overview
  • 11.12.3 Bausch Health Sales, Revenue and Gross Margin (2015-2020)
  • 11.12.4 Bausch Health Products Offered
  • 11.12.5 Bausch Health Related Developments
• 11.13 Acadia
  • 11.13.1 Acadia Corporation Information
  • 11.13.2 Acadia Description and Business Overview
  • 11.13.3 Acadia Sales, Revenue and Gross Margin (2015-2020)
  • 11.13.4 Acadia Products Offered
  • 11.13.5 Acadia Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)

• 12.1 Parkinsons disease Drug Market Estimates and Projections by Region
  • 12.1.1 Global Parkinsons disease Drug Sales Forecast by Regions 2021-2026
  • 12.1.2 Global Parkinsons disease Drug Revenue Forecast by Regions 2021-2026
• 12.2 North America Parkinsons disease Drug Market Size Forecast (2021-2026)
  • 12.2.1 North America: Parkinsons disease Drug Sales Forecast (2021-2026)
  • 12.2.2 North America: Parkinsons disease Drug Revenue Forecast (2021-2026)
  • 12.2.3 North America: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)
• 12.3 Europe Parkinsons disease Drug Market Size Forecast (2021-2026)
  • 12.3.1 Europe: Parkinsons disease Drug Sales Forecast (2021-2026)
  • 12.3.2 Europe: Parkinsons disease Drug Revenue Forecast (2021-2026)
  • 12.3.3 Europe: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)
• 12.4 Asia Pacific Parkinsons disease Drug Market Size Forecast (2021-2026)
  • 12.4.1 Asia Pacific: Parkinsons disease Drug Sales Forecast (2021-2026)
  • 12.4.2 Asia Pacific: Parkinsons disease Drug Revenue Forecast (2021-2026)
  • 12.4.3 Asia Pacific: Parkinsons disease Drug Market Size Forecast by Region (2021-2026)
• 12.5 Latin America Parkinsons disease Drug Market Size Forecast (2021-2026)
  • 12.5.1 Latin America: Parkinsons disease Drug Sales Forecast (2021-2026)
  • 12.5.2 Latin America: Parkinsons disease Drug Revenue Forecast (2021-2026)
  • 12.5.3 Latin America: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)
• 12.6 Middle East and Africa Parkinsons disease Drug Market Size Forecast (2021-2026)
  • 12.6.1 Middle East and Africa: Parkinsons disease Drug Sales Forecast (2021-2026)
  • 12.6.2 Middle East and Africa: Parkinsons disease Drug Revenue Forecast (2021-2026)
  • 12.6.3 Middle East and Africa: Parkinsons disease Drug Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter's Five Forces Analysis
• 13.5 Primary Interviews with Key Parkinsons disease Drug Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Parkinsons disease Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details